Humoral immune response to functional regions of human cytomegalovirus glycoprotein B

Journal of Medical Virology

Volumn 52, Issue 4, 1997, Pages 451-459

  Navarro, David ^a,c   Lennette, Evelyne ^b   Tugizov, Sharof ^a   Pereira, Lenore ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Virolab Inc   (United States)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Epitope specificity; Neutralizing antibodies; Subunit vaccine; Syncytium formation

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ARTICLE; CONVALESCENCE; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PROTEIN DOMAIN; SYNCYTIUM; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BINDING, COMPETITIVE; CARRIER STATE; CASE-CONTROL STUDIES; COS CELLS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOPATHOGENIC EFFECT, VIRAL; EPITOPE MAPPING; EPITOPES; HUMANS; MICE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; SEQUENCE DELETION; VIRAL ENVELOPE PROTEINS;

CYTOMEGALOVIRUS; EUKARYOTA; HUMAN HERPESVIRUS 5; MURINAE;

EID: 0030741688     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J     Document Type: Article

References (51)

1. Adler SP (1996): Current prospects for immunization against cytomegaloviral disease. Infectious Agents and Disease 5:29-35.
2. Alford CA, Britt WJ (1993): Cytomegalovirus. In Roizman B, Whitley RJ, Lopez C (eds): "The Human Herpesviruses." New York: Raven, pp 227-255.
3. Andreoni M, Faircloth M, Vulgar L, Britt W (1989): A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. Journal of Virological Methods 23:157-168.
4. Ayata M, Sugano T, Murayama T, Sakamuro D, Takegami T, Matsumoto Y, Furukawa T (1994): Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. Journal of Medical Virology 43:386-392.
5. Banks T, Huo B, Kousoulas K, Spaete R, Pachl C, Pereira L (1989): A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. Journal of General Virology 70:979-985.
6. Basgoz N, Qadri I, Navarro D, Sears A, Lennette E, Youngblom J, Pereira L (1992): The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains. Journal of General Virology 73:983-988.
7. Britt WJ, Vugler LG (1990): Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections. Journal of Infectious Diseases 161: 214-219.
8. Britt WJ, Vugler L, Stephens EB (1988): Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). Journal of Virology 62:3309-3318.
9. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990): Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64:1079-1085.
10. Brown JM, Kaneshima H, Mocarski ES (1995): Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. Journal of Infectious Diseases 171:1599-1603.
11. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR (1996): Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. Journal of Virology 70:78-83.
12. Cremer N, Cossen CK, Shell GR, Pereira L (1985): Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays. Journal of Clinical Microbiology 21:517-521.
13. Detrick B, Rhame J, Wang Y, Nagineni CN, Hooks JJ (1996): Cytomegalovirus replication in human retinal pigment epithelial cells. Altered expression of viral early proteins. Investigative Ophthalmology and Visual Science 37:814-825.
14. Drew L (1988): Cytomegalovirus infection in patients with AIDS. Journal of Infectious Diseases 158:449-456.
15. Gonczol E, Hudecz F, Ianacone J, Dietzschold B, Starr S, Plotkin SA (1986): Immune responses to isolated human cytomegalovirus envelope proteins. Journal of Virology 58:661-664.
16. Gonczol E, Ianacone J, Ho WZ, Starr S, Meigneir B, Plotkin S (1990): Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8:130-136.
17. Ho M (1991): "Cytomegalovirus: Biology and Infection." New York: Plenum.
18. Hopkins JI, Fiander AN, Evands AS, Delchambre M, Gheysen D, Borysiewicz LK (1996): Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B. Journal of Medical Virology 49:124-131.
19. Kniess N, Mach M, Fay J, Britt WJ (1991): Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. Journal of Virology 65:138-146.
20. Lasry S, Deny P, Asselot C, Rauzy M, Boucher J, Guyot C, Leroux MC, Livartowski A, Reinert P, Nicolas JC (1996): Interstrain variations in the cytomegalovirus (CMV) glycoprotein B gene sequence among CMV-infected children attending six day care centers. Journal of Infectious Diseases 174:606-609.
21. Liu YC, Kari B, Gehrz RC (1988): Human immune responses to major human cytomegalovirus glycoprotein. Journal of Virology 62: 1066-1070.
22. Liu Y-NC, Klaus A, Kari B, Stinski MF, Eckhardt K, Gehrz RC (1991): The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B-and T-cell immune responses in humans. Journal of Virology 65:1644-1648.
23. Lussenhop NO, Goertz R, Wabuke-Bunoti M, Gehrz R, Kari B (1988): Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology 164:362-372.
24. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL (1992): Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. Journal of Infectious Diseases 165:381-384.
25. Marshall GS, Stout GG, Knights ME, Rahalais GP, Ashley R, Miller H, Rossier E (1994): Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. Journal of Medical Virology 43:77-83.
26. Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987): Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68:1457-1461.
27. Meyer H, Masuho Y, Mach M (1990): The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. Journal of General Virology 71:2443-2450.
28. Meyer H, Sundquist V-A, Pereira L, Mach M (1992): Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology 73:2375-2383.
29. Mocarski ES, Bonyhadi M, Salimi S, McCune JM, Kaneshima H (1993): Human cytomegalovirus in a SCID-hu mouse: Thymic epithelial cells are prominent targets of viral replications. Proceedings of the National Academy of Sciences of the United States of America 90:104-108.
30. Navarro D, Paz P, Tugizov S, Topp K, LaVail J, Pereira L (1993): Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, the transmission of infection from cell to cell, and fusion of infected cells. Virology 197:143-158.
31. Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA (1993): Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. Journal of Virology 67:703-710.
32. Pass RF, August AM, Dworsky M, Reynolds DW (1982): Cytomegalovirus infection in a day-care center. New England Journal of Medicine 307:477-479.
33. Pereira L (1994): Function of glycoprotein B homologues of the family herpesviridae. Infectious Agents and Disease 3:9-28.
34. Pereira L, Hoffman M, Cremer N (1982): Electrophoretic analysis of polypeptides immune precipitated from extracts of cytomegalovirus infected cells by human sera. Infection and Immunity 36:933-942.
35. Pereira L, Stagno S, Hoffman M, Volanakis J (1983): Cytomegalovirus infected cell polypeptides immune precipitated by children with congenital and perinatal cytomegalovirus infections. Infection and Immunity 39:100-108.
36. Pereira L, Hoffman M, Tatsuno M, Dondero D (1984): Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies. Virology 139:73-86.
37. Pereira L, Basgoz N, Navarro D, Qadri I, Youngblom J, Sears A, Lennette E (1991): Mapping conserved antigenic regions and strain-specific epitopes within the glycoprotein B gene of human cytomegalovirus. In Landini PM (ed): "Progress in Cytomegalovirus Research: Proceedings of the Third International Cytomegalovirus Workshop." Amsterdam: Elsevier, pp 195-198.
38. Pereira L, Lennette E, Paz P, Navarro D (1993): Humoral immunity to glycoprotein B in primary and recurrent human cytomegalovirus infections. In Landini PM (ed): "Progress in Cytomegalovirus Research: Proceedings of the Third International Cytomegalovirus Workshop." Amsterdam: Elsevier, pp 145-148.
39. Plotkin SA (1994): Cytomegalovirus vaccines. In Plotkin SA, Mortimer EA (eds): "Vaccines." Philadelphia: W.B. Saunders, pp 803-807.
40. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K (1990): Vaccines for the prevention of human cytomegalovirus infection. Review of Infectious Diseases 12:827-838.
41. Qadri I, Navarro D, Paz P, Pereira L (1992): Assembly of conformation-dependent neutralizing domains on human cytomegalovirus glycoprotein B. Journal of General Virology 73:2913-2921.
42. Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC (1991): Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. Journal of Infectious Diseases 164:835-842.
43. Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck CA, Mach M (1996): Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216:133-145.
44. Silvestri M, Sundqvist VA, Ruden U, Wahren B (1991): Characterization of a major antigenic region on gp55 of human cytomegalovirus. Journal of General Virology 72:3017-3023.
45. Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L (1994): Function of human cytomegalovirus glycoprotein B: Syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201:263-276.
46. Tugizov S, Wang Y, Qadri I, Navarro D, Maidji E, Pereira L (1995): Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation. Virology 209:580-591.
47. Tugizov S, Maidji E, Pereira L (1996): Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells. Journal of General Virology 77: 61-74.
48. Utz U, Britt W, Vugler L, Mach M (1989): Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 5:1995-2001.
49. Wagner B, Kropff B, Kalbacher H, Britt W, Sundqvist VA, Ostberg L, Mach M (1992): A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. Journal of Virology 66:5290-5297.
50. Wang JB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA (1996): Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. Journal of Infectious Diseases 174:387-392.
51. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL (1996): The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84:769-799.